• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Molecular mechanism of epithelial-mesenchymal transition induced by EGFR tyrosine kinase inhibitors and development of EMT suppression therapy

Research Project

Project/Area Number 21K07106
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 50010:Tumor biology-related
Research InstitutionTokyo Medical University

Principal Investigator

Hiramoto Masaki  東京医科大学, 医学部, 教授 (70297828)

Co-Investigator(Kenkyū-buntansha) 川原 玄理  東京医科大学, 医学部, 准教授 (40743331)
Project Period (FY) 2021-04-01 – 2024-03-31
Project Status Completed (Fiscal Year 2023)
Budget Amount *help
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2023: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2022: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2021: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Keywordsがん / チロシンキナーゼ阻害薬 / 上皮間葉転換 / 浸潤・転移 / アクチン細胞骨格 / GAK
Outline of Research at the Start

がんの克服には、再発・転移の制御が重要である。転移の始まりは局所からの浸潤であり、浸潤能の獲得には、上皮間葉転換(EMT)が鍵となる。我々は、EGFRチロシンキナーゼ阻害薬の副次的標的分子であるcyclin G associated kinase (GAK)の欠損によって、EMTが誘導されることを独自に見出した。本研究では、EMTの分子基盤解明とEMT抑制による浸潤・転移の克服を目的として、①EMTにおけるGAKの分子機能と生理作用の解析、②モデル動物による転移能の検証、③EMT抑制化合物のスクリーニングと検証を行う。

Outline of Final Research Achievements

Cyclin G-associated kinase (GAK), a secondary target molecule of the tyrosine kinase inhibitor (TKI) gefitinib, has been demonstrated to suppress epithelial-mesenchymal transition (EMT) in cancer cells. It has also been shown that the inhibition of EMT by GAK is related to the kinase activity of GAK, suggesting that TKIs such as gefitinib, which inhibit the kinase activity of GAK, may induce EMT and induce invasion and metastasis of cancer cells. In addition, it has become clear that GAK regulates myosin phosphatase as a molecular mechanism involved in the reorganization of the actin cytoskeleton, one of the characteristics of EMT, and a new pathway has been presented to develop EMT suppression therapy.

Academic Significance and Societal Importance of the Research Achievements

GAKの生理機能としては、エンドサイトーシスや細胞周期制御に関わることが報告されており、我々の解析でオートファジー制御にも関わることが示されていたが、EMTや、がんの浸潤・転移との関連は不明であった。本研究では、GAKがEMTに対して抑制的に働くことが明らかとなり、その分子機序の一端が明らかとなった。生理的・病理的に重要なプロセスであるEMTの分子基盤について、統合的理解の深化に繋がる成果と考えられる。また今後、浸潤・転移の予防・抑制によるがんの克服と、臓器の線維化などEMTを背景とする臨床課題への応用展開に結びつく可能性を提示する成果としても重要である。

Report

(4 results)
  • 2023 Annual Research Report   Final Research Report ( PDF )
  • 2022 Research-status Report
  • 2021 Research-status Report
  • Research Products

    (17 results)

All 2023 2022 2021 Other

All Journal Article (8 results) (of which Int'l Joint Research: 1 results,  Peer Reviewed: 8 results,  Open Access: 8 results) Presentation (7 results) Remarks (2 results)

  • [Journal Article] Azithromycin, a potent autophagy inhibitor for cancer therapy, perturbs cytoskeletal protein dynamics2023

    • Author(s)
      Takano Naoharu、Hiramoto Masaki、Yamada Yumiko、Kokuba Hiroko、Tokuhisa Mayumi、Hino Hirotsugu、Miyazawa Keisuke
    • Journal Title

      British Journal of Cancer

      Volume: - Issue: 10 Pages: 1838-1849

    • DOI

      10.1038/s41416-023-02210-4

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Clarithromycin overcomes stromal cell-mediated drug resistance against proteasome inhibitors in myeloma cells via autophagy flux blockage leading to high NOXA expression2023

    • Author(s)
      Shota Moriya, Hiromi Kazama, Hirotsugu Hino, Naoharu Takano, Masaki Hiramoto, Shin Aizawa, Keisuke Miyazawa
    • Journal Title

      PLOS ONE

      Volume: 18 Issue: 12 Pages: e0295273-e0295273

    • DOI

      10.1371/journal.pone.0295273

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Ricolinostat enhances adavosertib‑induced mitotic catastrophe in TP53‑mutated head and neck squamous cell carcinoma cells2022

    • Author(s)
      Miyake K, Takano N, Kazama H, Kikuchi H, Hiramoto M, Tsukahara K, Miyazawa K.
    • Journal Title

      Int J Oncol.

      Volume: 60 Issue: 5 Pages: 54-54

    • DOI

      10.3892/ijo.2022.5344

    • Related Report
      2022 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Kana Miyahara, Naoharu Takano, Yumiko Yamada, Hiromi Kazama, Mayumi Tokuhisa, Hirotsugu Hino, Koji Fujita, Edward Barroga, Masaki Hiramoto, Hiroshi Handa, Masahiko Kuroda, Takashi Ishikawa & Keisuke Miyazawa BRCA1 degradation in response to mitochondrial damage in breast cancer cells2021

    • Author(s)
      Kana Miyahara, Naoharu Takano, Yumiko Yamada, Hiromi Kazama, Mayumi Tokuhisa, Hirotsugu Hino, Koji Fujita, Edward Barroga, Masaki Hiramoto, Hiroshi Handa, Masahiko Kuroda, Takashi Ishikawa, Keisuke Miyazawa
    • Journal Title

      Scientific Reports

      Volume: 11 Issue: 1 Pages: 8735-8735

    • DOI

      10.1038/s41598-021-87698-7

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Azithromycin enhances the cytotoxicity of DNA‐damaging drugs via lysosomal membrane permeabilization in lung cancer cells2021

    • Author(s)
      Toriyama Kazutoshi、Takano Naoharu、Kokuba Hiroko、Kazama Hiromi、Moriya Shota、Hiramoto Masaki、Abe Shinji、Miyazawa Keisuke
    • Journal Title

      Cancer Science

      Volume: 112 Issue: 8 Pages: 3324-3337

    • DOI

      10.1111/cas.14992

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Induction of synergistic non-apoptotic cell death by simultaneously targeting proteasomes with bortezomib and histone deacetylase 6 with ricolinostat in head and neck tumor cells2021

    • Author(s)
      Hattori Kazuhiro、Takano Naoharu、Kazama Hiromi、Moriya Shota、Miyake Keitaro、Hiramoto Masaki、Tsukahara Kiyoaki、Miyazawa Keisuke
    • Journal Title

      Oncology Letters

      Volume: 22 Issue: 3 Pages: 680-680

    • DOI

      10.3892/ol.2021.12941

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Targeted disruption of GAK stagnates autophagic flux by disturbing lysosomal dynamics2021

    • Author(s)
      Miyazaki Masaya、Hiramoto Masaki、Takano Naoharu、Kokuba Hiroko、Takemura Jun、Tokuhisa Mayumi、Hino Hirotsugu、Kazama Hiromi、Miyazawa Keisuke
    • Journal Title

      International Journal of Molecular Medicine

      Volume: 48 Issue: 4 Pages: 195-195

    • DOI

      10.3892/ijmm.2021.5028

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Lysosome-targeted drug combination induces multiple organelle dysfunctions and non-canonical death in pancreatic cancer cells2021

    • Author(s)
      Suzuki S, Ogawa M, Miyazaki M, Ota K, Kazama H, Hirota A, Takano N, Hiramoto M, Miyazawa K.
    • Journal Title

      Oncology Reports

      Volume: 47 Issue: 2 Pages: 40-40

    • DOI

      10.3892/or.2021.8251

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access
  • [Presentation] CDK4/6阻害薬abemaciclibが誘導する細胞死と連動した空胞形成のメカニズムの検討2023

    • Author(s)
      3.日野浩嗣, 田中良法, 池田俊勝, 原知世, 竹谷浩介, 高野直治, 平本正樹, 相澤信, 宮澤啓介, 江藤真澄, 平井宗一
    • Organizer
      第96回日本生化学会大会
    • Related Report
      2023 Annual Research Report
  • [Presentation] Actin cytoskeleton reorganization mediated by GAK, a cellular target of gefitinib2022

    • Author(s)
      Hiramoto M, Takano N, Kazama H, Miyazawa K.
    • Organizer
      第81回日本癌学会学術集会
    • Related Report
      2022 Research-status Report
  • [Presentation] Azithromycin enhances DNA-damaging drug-induced lysosomal membrane permeability and cytotoxicity2021

    • Author(s)
      Takano N, Hiramoto M, Kazama H, Moriya S, Miyazawa K.
    • Organizer
      第80回日本癌学会学術集会
    • Related Report
      2021 Research-status Report
  • [Presentation] Fingolimod enhances lapatinib-induced cell death in pancreatic cancer cells with multiple organelle dysfunctions2021

    • Author(s)
      Ogawa M, Suzuki S, Hiramoto M, Kazama H, Takano N, Miyazawa K.
    • Organizer
      第80回日本癌学会学術集会
    • Related Report
      2021 Research-status Report
  • [Presentation] CDK4/6阻害薬abemaciclibが誘導する空胞の形成メカニズムの検討2021

    • Author(s)
      日野浩嗣, 田中良法, 竹谷浩介, 高野直治, 平本正樹, 相澤信, 宮澤啓介, 江藤真澄, 平井宗一.
    • Organizer
      第94回日本生化学会大会
    • Related Report
      2021 Research-status Report
  • [Presentation] アジスロマイシンはリソファジ―を阻害しリソソーム膜透過性を亢進させることでDNA障害性薬剤による細胞死を増強する2021

    • Author(s)
      鳥山和俊, 高野直治, 國場寛子, 風間宏美, 森谷昇太, 平本正樹, 阿部信二, 宮澤啓介.
    • Organizer
      第94回日本生化学会大会
    • Related Report
      2021 Research-status Report
  • [Presentation] サイクリンG関連キナーゼGAKによるオートファジー・リソソーム系の調節にはアクトミオシンの制御が関与する2021

    • Author(s)
      平本正樹, 宮﨑誠也, 高野直治, 國場寛子, 武村淳, 徳久真弓, 日野浩嗣, 風間宏美, 宮澤啓介.
    • Organizer
      第94回日本生化学会大会
    • Related Report
      2021 Research-status Report
  • [Remarks] 東京医科大学 分子標的探索センター

    • URL

      http://www.tokyo-med.ac.jp/target/

    • Related Report
      2023 Annual Research Report 2022 Research-status Report
  • [Remarks] 東京医科大学 分子標的探索センター

    • URL

      http://www.tokyo-med.ac.jp/target/index.html

    • Related Report
      2021 Research-status Report

URL: 

Published: 2021-04-28   Modified: 2025-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi